Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).
Prostaglandin E2 (PGE2) regulates inflammation and the tumor microenvironment, thought to happen through engagement with the E-type prostanoid EP2 and EP4 receptors, exerting immunosuppression in the tumor microenvironment. The simultaneous blockade of EP2 and EP4 – not blocking either alone – is needed to overcome this immunosuppressor effect.
Vincerx Pharma Inc. has described drug conjugates comprising prodrugs of cyclin-dependent kinase 9 (CDK9) inhibitors covalently linked to an integrin binding moiety through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, cardiac hypertrophy and macular degeneration.
RSS
